eISSN: 2345-2781  
Submitted: 05 Feb 2018

Accepted: 25 Jul 2018
First published online: 13 Aug 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

Abstract Page Views: 68
PDF Downloads: 72
Full Text Views: 0
J Renal Inj Prev. 2019;8(1):44-49.
doi: 10.15171/jrip.2019.09

Original

Therapeutic efficacy of erythropoietin alfa and erythropoietin beta in hemodialysis; a randomized controlled trial

Hamid-Reza Omrani 1, Sima Golmohhamadi 1 * , Amir-Hossein Hashemian 2, Ali-Zaman Vaysmoradi 1, Roya Safari-Faramani 2

1 Nephrology and Urology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran 2
2 Department of Biostatistics, Kermanshah University of Medical Sciences, Kermanshah, Iran
*Corresponding author: Sima Golmohhamadi, Email: Email: simag_2000@yahoo.com

Abstract

Introduction: Anemia, as a common complication of end-stage renal disease (ESRD), usually develops due to erythropoietin deficiency. Recombinant human erythropoietins (rHEPOs) are indicated for the correction of renal anemia.

Objectives: We aimed to evaluate the efficacy of a new brand of erythropoietin named CinnaPoietin (erythropoietin beta) on hemoglobin levels.

Patients and Methods: This is a randomized double-blinded controlled trial. Ninety-six ESRD patients on hemodialysis recruited in the study, whose hemoglobin levels was less than 10 g/dL. They allocated to two groups. PDPoetin (erythropoietin alfa) 50-100 U/kg three times per week intravenously administrated to the control group and CinnaPoietin with exactly same regimen as like PDPoetin group administrated for the rest of the participants. The study duration was 3 months. We measured plasma hemoglobin monthly for 3 months.

Results: We found, hemoglobin was increased across the time and it was statistically significant (P<0.001), while there was no statistically significant differences between the groups (P=0.712).

Conclusion: According to the result of the present study there is no statistical significant difference between these two brands of exogenous rHEPO in the case of increasing the hemoglobin concentration.

Implication for health policy/practice/research/medical education:

In a randomized controlled trial on 96 end-stage renal disease (ESRD) patients on hemodialysis, we found that administration of both brands (CinnaPoietin versus PDPoetin) of recombinant human erythropoietin is equally effective to increase the hemoglobin concentration in ESRD patients on hemodialysis.

Please cite this paper as: Omrani HR, Golmohhamadi S, Hashemian AH, Vaysmoradi AZ, Safari-Faramani RS. Therapeutic efficacy of erythropoietin alfa and erythropoietin beta in hemodialysis; a randomized controlled trial. J Renal Inj Prev. 2019;8(1):44-47. DOI: 10.15171/jrip.2019.09.

First name
 
Last name
 
Email address
 
Comments
 
Security code